FSGS Recurrence Collaboration: Report of a Symposium.
FSGS Recurrence Collaboration: Report of a Symposium.
复制标题
FSGS 重复协作：研讨会报告。
DOI：
10.1159/000535138
复制
发表时间：
2024
期刊：
影响因子：
--
通讯作者：
Jackson,
中科院分区：
文献类型：
--
作者：
Gipson,DebbieS;Wang,Chia-Shi;Salmon,Eloise;Gbadegesin,Rasheed;Naik,Abhijit;Sanna-Cherchi,Simone;Fornoni,Alessia;Kretzler,Matthias;Merscher,Sandra;Hoover,Paul;Kidwell,Kelley;Saleem,Moin;Riella,Leonardo;Holzman,Lawrence;Jackson,
FSGS描述了继发于足细胞损伤和耗竭的组织学病变[1-3]。目前，我们很少有工具来区分原发性或特发性、遗传性或继发于各种疾病（高血压、肥胖、药物、病毒等）的FSGS形式，以及疾病复发的风险。该病的发病率在整个生命周期中相当稳定，约占新发肾病综合征病例的10-20%。此外，在所有进行性肾功能丧失并需要肾脏替代治疗的患者中，FSGS是5 - 10%的潜在疾病[4,5]。
FSGS describes a histologic lesion secondary to podocyte injury and depletion [1‒3]. We currently have very few tools to discriminate between primary or idiopathic, genetic, or forms of FSGS secondary to diverse conditions (hypertension, obesity, drugs, viruses, and others) and the risk of recurrent disease [4]. The incidence of the disease is fairly constant across the lifespan accounting for approximately 10–20% of cases of new-onset nephrotic syndrome. Moreover, FSGS is the underlying disease in 5–10% of all patients who have progressive loss of kidney function and require renal replacement therapy [4, 5].